|
See related Aclasta inj information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Zoledronic acid |
|
Indications |
Listed in Dosage.
Click to view Aclasta detailed prescribing infomation |
|
Dosage |
Postmenopausal osteoporosis, osteoporosis in men, prevention of clinical fractures after hip fracture 5 mg IV infusion once a year. Paget's disease 5 mg single IV infusion. Administer over at least 15 min.
Click to view Aclasta detailed prescribing infomation |
|
Overdosage |
View Aclasta overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to bisphosphonates. Hypocalcemia. Pregnancy & lactation.
Click to view Aclasta detailed prescribing infomation |
|
Special Precautions |
Severe renal impairment. Ensure appropriate hydration prior to administration. Adequate Ca & vit D intake prior to Aclasta therapy in patients w/ preexisting hypocalcemia, & for 10 days following Aclasta in patients w/ Paget's disease of bone. Monitor for other mineral metabolism disorders; avoid invasive dental procedures for those who develop osteonecrosis of the jaw.
Click to view Aclasta detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, dizziness, dyspnea, nausea, vomiting, diarrhea, myalgia, arthralgia, bone & back pain, pain in extremities, fever, hypocalcemia, flu-like symptoms, chills, fatigue, asthenia, malaise, rigors.
View ADR Monitoring Form |
|
Drug Interactions |
Nephrotoxic drugs eg aminoglycosides, or diuretics that may cause dehydration.
View more drug interactions with Aclasta |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Aclasta detailed prescribing infomation |
|
Storage |
View Aclasta storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Aclasta description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Aclasta mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Aclasta injection |
|
Aclasta 5 mg/100 mL x 1's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig
|
|
|
|
